ARTICLE: Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes
AUTHORS: Peter Abadir, Alka Jain, Laura Powell, Qian-Li Xue, Jing Tian, Robert G. Hamilton, David Bennett, Thomas Finucane, Jeremy D. Walston, Neal S. Fedarko
JOURNAL: Circulation. 2016 Nov 30. pii: CIRCULATIONAHA.116.022385. [Epub ahead of print]
BACKGROUND: -Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be utilized to stratify patient risk and to identify patients who can benefit from angiotensinreceptor blocker (ARB) treatment.
METHODS: -Demographic and physiologic covariates were measured in a discovery set of community dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of ARB treatment.
RESULTS: -The Baltimore group had 28 subjects with falls, 32 frail subjects and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r = 0.33, P < 0.0001), systolic BP (Spearman r = 0.28, P < 0.0001), body mass index (Spearman r = 0.28, P < 0.0001), weaker grip strength (Spearman r = -0.34, P < 0.01), and slower walking speed (Spearman r = -0.30, P < 0.05). Individuals with high AT1RaAbs were 3.9 (95% CI 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). Every 1 µg/ml increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, gender, BMI and BP. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r = - 0.57, P < 0.005), walking speed (Spearman r = - 0.47, P< 0.005) and falls (Spearman r = 0.30, P < 0.05). Every 1 µg/ml increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, gender, BMI and BP. Chronic treatment with ARBs was associated with better control of systolic BP and attenuation of decline in both grip strength and time to death.
CONCLUSIONS: -In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension and adverse outcomes. ARB treatment may blunt the harm associated with high levels of AT1RaAb.
For a link to the full article, click here: http://circ.ahajournals.org/content/early/2016/11/30/CIRCULATIONAHA.116.022385
Link to abstract online: https://www.ncbi.nlm.nih.gov/pubmed/?term=Discovery+and+Validation+of+Agonistic+Angiotensin+Receptor+Autoantibodies+as+Biomarkers+of+Adverse+Outcomes